natgillin/translations-raw huggingface dataset:
Clinical drug-drug interactions studies in healthy subjects indicated a reduced exposure to delamanid, of up to 45% following 15 days of concomitant administration of the strong inducer of cytochrome P450 (CYP) 3A4 (Rifampicin 300 mg daily) with delamanid (200 mg daily). 
45% nakon 15 dana istodobne primjene jakog induktora citokroma P450 (CYP) 3A4 (Rifampicin 300 mg dnevno) s delamanidom (200 mg dnevno).
• Increased blood tryglycerides 
• povišeni trigliceridi u krvi
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove:
Oropharyngeal pain Throat irritation Dry throat* Rhinorrhoea* 
Poremećaji dišnog sustava, prsišta i sredoprsja dispneja kašalj orofaringealna bol iritacija grla suho grlo* rinoreja*
Susceptibility testing breakpoints 
Testiranje granične koncentracije osjetljivosti
• Hot flushes 
• navale vrućine
Skin and subcutaneous tissue disorders 
Poremećaji bubrega i mokraćnog retencija mokraće dizurija*
• Reduced sensation 
• smanjen osjet
• Drug- resistance 
• Rezistenciju na lijek
The PRAC noted the recurrent concomitant use of delamanid with bedaquiline in patients experiencing QTc prolongation. 
PRAC je zabilježio rekurentnu istodobnu primjenu delamanida s bedakilinom u bolesnika s produljenjem
No dose adjustment is considered necessary in patients with mild or moderate renal impairment. 
Prilagodba doze nije potrebna u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega.
Tablet core 
sustava nokturija
Rash maculo-papular* Rash* 
pruritus* makulopapulozni osip* osip* akne hiperhidroza
Tinnitus 
astenija
• SmPC 
• omaglica
- Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval or QTc > 500 ms. - History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia. 
- Anamneza simptomatskih srčanih aritmija ili klinički relevantna bradikardija.
Eosinophilic pustular folliculitis* Pruritus generalised* Rash erythematous 
Poremećaji kože i potkožnog tkiva alopecija* eozinofilni pustularni folikulitis* generalizirani pruritus* eritematozni osip dermatitis urtikarija pruritični osip*
Abdominal pain upper 
mučnina bol u gornjem dijelu abdomena
• Drowsiness 
• omamljenost
Tel: +39 (0)2 00632710 
Otsuka Pharmaceutical Italy S.r.l. Tel: +39 (0)2 00632710
Read the package leaflet before use. 
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije upotrebe pročitajte uputu o lijeku.
Ear and labyrinth disorders 
Poremećaji uha i labirinta bol u uhu tinitus
Tell your doctor... - if you are taking, have recently taken or might take any other medicines, including medicines or herbal remedies obtained without prescription, - if you are taking medicines to treat an abnormal heart rhythm (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol). 
Obavijestite svog liječnika... - ako uzimate ili ste nedavno uzimali ili biste mogli uzimati druge lijekove uključujući lijekove ili biljne lijekove dobivene bez recepta,
Feeling hot 
navala vrućine*
Anti-Tuberculosis medicines 
FARMACEUTSKI PODACI
• Decreased values for blood investigations for the hormone cortisol 
• smanjene vrijednosti hormona kortizola u krvnim pretragama • povišeni krvni tlak
Osteochondrosis Muscular weakness Musculoskeletal pain* Flank pain 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva osteohondroza mišićna slabost bol u mišićno-koštanom sustavu* bol u slabinama bol u ekstremitetima artralgija* mialgija*
Haemoptysis 
hemoptiza
Side effects commonly reported in clinical studies with Deltyba were: 
Nuspojave često prijavljene u kliničkim ispitivanjima s lijekom Deltyba bile su: • anemija
• Acne 
• osip • akne
No dose adjustment is considered necessary in patients with mild hepatic impairment. 
Prilagodba doze nije potrebna u bolesnika s blagim oštećenjem funkcije jetre.
• Stomach pain 
• herpes zoster
- Certain antimicrobial agents, including: - macrolides (e.g. erythromycin, clarithromycin) - moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones) - bedaquiline - triazole antifungal agents - pentamidine - saquinavir - Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine) - Certain antimalarials with QT-prolonging potential (e.g. halofantrine, quinine, chloroquine, artesunate/amodiaquine, dihydroartemisinin/piperaquine). 
- makrolide (npr. eritromicin, klaritromicin) - moksifloksacin, sparfloksacin (vidjeti dio 4.4 za primjenu s drugim fluorokinolonima) - bedakilin
Lethargy Balance disorder Radicular pain Poor quality sleep 
Poremećaji živčanog sustava letargija poremećaj ravnoteže radikularna bol loša kvaliteta sna periferna neuropatija somnolencija* hipoestezija omaglica* glavobolja parestezija tremor
- if you are taking medicines to treat psychoses (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine) or depression - if you are taking certain antimicrobial medicines (e.g. erythromycin, clarithromycin, moxifloxacin, sparfloxacin, bedaquiline, or pentamidine). 
- ako uzimate lijekove za liječenje psihoza (npr. fenotiazin, sertindol, sultoprid, klorpromazin, haloperidol,
• Increased blood pressure 
• povećan spolni nagon
• Hair loss 
• nastanak modrica
• Oral thrush 
• proljev
• Dizziness 
• koprivnjača
Teл. 
Deltyba.
SPECIAL STORAGE CONDITIONS 
Posebne okolnosti
Give either without food or with a small amount of food. 
Dajte proizvod bez hrane ili s malom količinom hrane.
ATCvet code: QM01AH91. 
ATCvet kod: QM01AH91.
Thereafter it is recommended to continue regular monitoring, e.g. every 3-6 months. 
Nakon toga preporučuje se nastaviti redovito praćenje, primjerice svakih 3 - 6 mjeseci.
Do not use in pregnant and lactating animals (see section 4.7). 
Ne primjenjivati na gravidnim životinjama i životinjama u laktaciji (vidjeti odjeljak 4.7).
Avoid introduction of contamination. 
Izbjegavajte kontaminaciju proizvoda.
In clinical studies, inadequate response to treatment was seen in 10-15% of the dogs. 
U kliničkim ispitivanjima neodgovarajući odgovor na liječenje uočen je u 10 - 15 % pasa.
The tablet(s) should be administered without food at least 30 minutes prior to surgery. 
Tabletu(e) treba primijeniti bez hrane najmanje 30 minuta prije kirurškog zahvata.
Date of last renewal: 08/11/2013. 
Datum posljednjeg produljenja odobrenja: 08/11/2013.
Once broached, use within 28 days by … 
Nakon otvaranja upotrijebite unutar 28 dana do…
Please note that the recommended doses for the two formulations are different. 
Vodite računa o tome da su preporučene doze za ta dva farmaceutska oblika drugačije.
If necessary, additional analgesic treatment with opioids is recommended. 
Ako je potrebno, preporučuje se dodatno analgetičko liječenje opioidima.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Ako zamijetite bilo koju nuspojavu, čak i one koje nisu navedene u ovoj uputi o VMP, ili mislite da veterinarsko-medicinski proizvod ne djeluje, molimo obavijestite svog veterinara.
Treatment should not exceed one dose (either tablet or injection) per day. 
Terapija ne bi smjela prelaziti jednu dozu (bilo tablete ili injekcije) na dan.
Premedication should only be carried out in combination with butorphanol-analgesia. 
Premedikaciju treba provesti samo u kombinaciji s analgezijom butorfanolom.
For any information about this veterinary medicinal product, please contact the marketing authorisation holder. 
Za bilo koju informaciju o ovom veterinarsko-medicinskom proizvodu, molimo kontaktirajte nositelja odobrenja za stavljanje u promet.
A clinical response is normally seen within a week. 
Klinički odgovor obično se uočava unutar tjedan dana.
Sodium metabisulphite (E 223) 
Natrijev metabisulfit (E 223)
Please refer to section 4.5. 
Vidjeti odjeljak 4.5.
Robenacoxib tablets are therefore COX-1 sparing at recommended doses in dogs. 
Tablete robenakoksiba stoga štede COX-1 pri preporučenim dozama u pasa.
Do not administer with food since clinical trials demonstrated better efficacy of robenacoxib when administered without food or at least 30 minutes before or after a meal. 
Nemojte primjenjivati proizvod s hranom jer su klinička ispitivanja pokazala bolju djelotvornost robenakoksiba kad se primjenjivao bez hrane ili najmanje 30 minuta prije ili nakon obroka.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 
U nedostatku ispitivanja kompatibilnosti, ovaj veterinarsko-medicinski proizvod ne smije se miješati s drugim veterinarsko-medicinskim proizvodima.
Reversible inflammation at the injection site was noted in all groups (including controls) and was more severe in the 6 and 20 mg/kg dose groups. 
Reverzibilna upala na mjestu injekcije zabilježena je u svim grupama (uključujući kontrolne) i bila je teža u grupama koje su primale doze od 6 i 20 mg/kg.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16/12/2008. 
Datum prvog odobrenja: 16/12/2008.
Treatment should be discontinued after 10 days if no clinical improvement is apparent. 
Liječenje treba prekinuti nakon 10 dana ako nema vidljivog kliničkog poboljšanja.
The tablets should not be divided or broken. 
Tablete se ne smiju lomiti ili dijeliti na dijelove.
In a clinical study, 10 of 35 CMSD cats were assessed to be significantly more active when treated with robenacoxib for three weeks compared to these same cats when they received a placebo treatment. 
U kliničkom ispitivanju 10 od 35 CMSD mačaka procijenjeno je kao znatno aktivnije kad su tri tjedna primale robenakoksib u usporedbi s istim mačkama kad su dobivale placebo.
In dogs treated up to 2 weeks no increases in liver enzyme activities were observed. 
U pasa liječenih do dva tjedna nije bilo porasta u aktivnostima jetrenih enzima.
For long term therapy, liver enzymes should be monitored at the start of therapy, e.g. after 2, 4 and 8 weeks. 
Pri dugoročnom liječenju treba nadzirati jetrene enzime na početku liječenja, primjerice nakon 2, 4 i 8 tjedana.
Wash hands and exposed skin immediately after use of the product. 
Operite ruke i izloženu kožu odmah nakon primjene proizvoda.
6 to 12 
6 do 12
The cyclooxygenase enzyme (COX) is present in two forms. 
Enzim ciklooksigenaza (COX) pojavljuje se u dvama oblicima.
The biological relevance of increased QT intervals outside of normal variations observed following overdose of robenacoxib is unknown. 
Biološka relevantnost povećanih QT intervala izvan normalnih vrijednosti uočena nakon predoziranja robenakoksibom nije poznata.
Treatment should be discontinued after 6 weeks if no clinical improvement is apparent. 
Terapiju treba prekinuti nakon 6 tjedana ako nije vidljiv nikakav klinički napredak.
In very rare cases, lethargy may be observed. 
U vrlo rijetkim slučajevima moguća je pojava letargije.
Reversible, minimal injection site reactions were noted in both dose groups. 
Reverzibilne minimalne reakcije na mjestu injekcije uočene su u objema grupama doziranja.
Ethanol, anhydrous Poloxamer 188 
Etanol, bezvodni Poloksamer 188
PHARMACEUTICAL FORM Solution for injection. 
OBLIK Otopina za injekcije.
Response to long-term treatment should be monitored at regular intervals by a veterinary surgeon. 
Reakciju na dugotrajno liječenje treba pratiti u redovitim intervalima kod veterinara.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 
Pri utvrđivanju razdoblja bez liječenja ipak treba uzeti u obzir farmakokinetička svojstva prethodno primjenjivanih proizvoda.
Citric acid monohydrate Sodium metabisulphite (E 223) Sodium hydroxide Water for injections 
Monohidrat limunske kiseline Natrijev metabisulfit (E 223) Natrijev hidroksid Voda za injekcije
The following number of tablets should be given once daily at the same time every day. 
Sljedeći broj tableta treba davati jedanput na dan u isto vrijeme svaki dan.
40 to 80 
40 do 80
After a subcutaneous administration of 1 mg/kg the systemic bioavailability is 69% in cats and 88% in dogs. 
Nakon subkutane primjene od 1 mg/kg sustavna bioraspoloživost iznosi 69 % u mačaka i 88 % u pasa.
Chronic musculo-skeletal disorders: Duration of treatment should be decided on an individual basis. 
Kronični mišićno-koštani poremećaji: O trajanju terapije treba odlučiti na individualnoj osnovi.
In overdose studies conducted in cats, there was a dose-dependent increase in the QT interval. 
U studijama ispitivanja predoziranja provedenim na mačkama postojalo je povećanje QT intervala povezano s doziranjem.
Accumulation of metabolites has not been tested. 
Akumulacija metabolita nije ispitana.
The systemic bioavailability of robenacoxib tablets in dogs was 62% with food and 84% without food. 
Sustavna bioraspoloživost tableta robenakoksiba u pasa iznosila je 62 % s hranom i 84 % bez hrane.
NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Onsior 6 mg
Shelf life after first broaching of the vial: 28 days. 
Rok valjanosti poslije prvog otvaranja bočice: 28 dana.
Bioaccumulation of metabolites has not been tested. 
Bioakumulacija metabolita nije ispitana.
Robenacoxib/tablet 
Robenakoksib/tableta
Orthopaedic surgery: Give as a single oral treatment prior to orthopaedic surgery. 
Ortopedski kirurški zahvat: Proizvod dajte kao jednokratnu terapiju kroz usta prije ortopedskog kirurškog zahvata.
Manufacturer responsible for the batch release: Elanco France S.A.S 
Proizvođač odgovoran za puštanje serije u promet: Elanco France S.A.S
Solution for injection: Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE 
Otopina za injekcije: Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCUSKA
SPECIAL STORAGE CONDITIONS Store below 25 °C. 
POSEBNI UVJETI ČUVANJA Čuvati pri temperaturi do 25 °C.
Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE 
Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCUSKA
The cyclooxygenase 1 enzyme (COX-1) which has protective functions, e.g. in the digestive tract and kidneys, is not inhibited by robenacoxib. 
Enzim ciklooksigenaza 1 (COX-1) koji ima zaštitne funkcije, primjerice u probavnom traktu i bubrezima, nije inhibiran robenakoksibom.
Diarrhoea, soft and dark faeces or reduced appetite were uncommon. 
Proljev, mekana i tamna stolica ili smanjen apetit bili su manje česti.
After surgery in cats, once daily treatment may be continued at the same dosage and at the same time every day for up to 2 days. 
Nakon kirurškog zahvata na mačkama liječenje jedanput na dan može se nastaviti u istoj dozi i u isto vrijeme svaki dan do dva dana.
Cats and dogs. 
Mačke i psi.
Robenacoxib also had no detrimental effects on cartilages or joints. 
Robenakoksib nije imao štetne učinke ni na hrskavicu ili zglobove.
The systemic bioavailability of robenacoxib tablets was 49% without food. 
Sustavna raspoloživost tableta robenakoksiba bez hrane iznosila je 49 %.
Store below 25 °C. 
Čuvati pri temperaturi do 25 °C.
EXPIRY DATE EXP {month/year} Once broached, use by … 
ROK VALJANOSTI EXP {mjesec/godina} Nakon otvaranja upotrijebite do…
For long-term treatment, once a clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time. 
Tijekom dugoročnog liječenja, nakon što se uoči klinički odgovor, doza Onsiora može se prilagoditi na najnižu djelotvornu pojedinu dozu, uzimajući u obzir da stupanj bola i upale povezanih s kroničnim osteoartritisom mogu varirati tijekom vremena.
A clinical response is normally seen within 3-6 weeks. 
Klinička reakcija obično je vidljiva u roku od 3 do 6 tjedana.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 
Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiven primjenom tih veterinarsko-medicinskih proizvoda treba odlagati u skladu s lokalnim propisima.
Administer once daily at the same time every day according to the table below. 
Primijenite proizvod jedanput na dan u isto vrijeme svaki dan u skladu s tablicom u nastavku.
Each tablet contains: 
Jedna tableta sadržava:
Peak blood concentrations of robenacoxib are attained rapidly after subcutaneous injection in cats and dogs. 
Apsorpcija Vršne koncentracije robenakoksiba u krvi postižu se brzo nakon subkutane injekcije u mačaka i pasa.
Moderate or severe pain at injection site was uncommon. 
Umjeren ili težak bol na mjestu injekcije bio je manje čest.
Refrigeration is not required during the 4-week in-use period after first broaching of the vial. 
Tijekom četverotjedne uporabe nakon prvog otvaranja bočice čuvanje u hladnjaku nije potrebno.
TARGET SPECIES Cats and dogs. 
CILJNE VRSTE ŽIVOTINJA Mačke i psi.
4.6 Adverse reactions (frequency and seriousness)* 
4.6 Nuspojave (učestalost i ozbiljnost)*
PHARMACEUTICAL FORM Solution for injection 
OBLIK Otopina za injekcije
Onsior solution for injection for cats and dogs is available in a cardboard box containing 1 vial with 20 ml solution for injection. 
Otopina za injekcije Onsior za mačke i pse dostupna je u kartonskoj kutiji koja sadržava jednu bočicu s 20 ml otopine za injekcije.
In most cases there were no clinical signs and the liver enzyme activities either stabilised or decreased with continued treatment. 
U većini slučajeva nije bilo kliničkih znakova, a aktivnosti jetrenih enzima stabilizirale su se ili smanjile s nastavkom liječenja.
2 tablets 
2 tablete
In most cases the liver enzyme activities either stabilised or decreased with continued treatment. 
U većini slučajeva aktivnosti jetrenih enzima stabilizirale su se ili smanjile s nastavkom liječenja.
NATURE/TYPE: Blister foil 
OSOBINE/TIP: Blister
Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring. 
Istodobnu primjenu s lijekovima koji djeluju na rad bubrega, primjerice s diureticima ili inhibitorima angiotenzin-konvertirajućeg enzima (ACE), treba klinički nadzirati.
The solution for injection is a clear, colourless to slightly coloured (pink) liquid. 
Otopina za injekciju je bistra, bezbojna do blago obojena (ružičasta) tekućina.
In the high dose group kidney weights were decreased and sporadically associated with renal tubular degeneration/ regeneration but not correlated with evidence of renal dysfunction on clinical pathology parameters. 
U grupi koja je dobivala visoke doze smanjena je težina bubrega što se sporadično povezivalo s renalnom tubularnom degeneracijom/regeneracijom, ali bez korelacije s dokazanom renalnom disfunkcijom prema kliničkim patološkim parametrima.
Do not use after the expiry date stated on the label or blister after EXP. 
Ne koristite veterinarsko medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi i blisteru poslije EXP.
After subcutaneous administration, the terminal half-life from blood was 1.1 h in cats and 1.2 h in dogs. 
Nakon subkutane primjene terminalni poluživot u krvi iznosio je 1,1 h u mačaka i 1,2 h u pasa.
Wash hands after use of the veterinary medicinal product. 
Operite ruke nakon primjene veterinarsko-medicinskog proizvoda.
Two cats were more active when given placebo and for the remaining 23 cats no significant difference in activity could be detected between robenacoxib and placebo treatment. 
Dvije mačke bilo su aktivnije kad su dobivale placebo, a kod ostalih 23 nisu uočene nikakve razlike u aktivnosti između terapije robenakoksibom i placebo.
Regular monitoring should be undertaken by the veterinarian. 
Veterinar treba redovito nadzirati liječenu životinju.
Mild and transient diarrhoea, soft faeces or vomiting were commonly reported in clinical trials with treatment up to 6 days. 
Blagi i prolazni proljev, mekana stolica ili povraćanje često su prijavljivani u kliničkim ispitivanjima s terapijom od najviše 6 dana.
Tablets are round, beige to brown and non-divisible. 
Tablete su okrugle, bež do smeđe boje i bez razdjelne crte.
However, with long-term treatment increases in liver enzyme activities were common. 
No uz dugoročno liječenje porasti u aktivnostima jetrenih enzima bili su česti.
Number of tablets by size 
Broj tableta po veličini
1 tablet 
1 tableta
6 x 1 tablets 12 x 1tablets 30 x 1 tablets 60 x 1 tablets 
6 x 1 tableta 12 x 1 tableta 30 x 1 tableta 60 x 1 tableta
The pharmacokinetics of robenacoxib do not differ between male and female cats. 
Nema razlike u farmakokinetici robenakoksiba između mužjaka i ženki mačke.
7 tablets 14 tablets 28 tablets 70 tablets 30 x 1 tablets 60 x 1 tablets 
7 tableta 14 tableta 28 tableta 70 tableta 30 x 1 tableta 60 x 1 tableta
Do not use in pregnant or lactating cats or cats used for breeding because the safety of this product has not been established in these animals. 
Ne primjenjivati na gravidnim mačkama, mačkama u laktaciji ili rasplodnim mačkama jer sigurnost ovog proizvoda nije utvrđena na tim životinjama.
In two clinical trials in (mainly indoor) cats with chronic musculo-skeletal disorder, robenacoxib increased the activity and improved subjective scores of activity, behaviour, quality of life, temperament and happiness of the cats. 
U dva klinička ispitivanja na mačkama (koje uglavnom borave u kući) s kroničnim mišićno-koštanim poremećajem robenakoksib je povećao aktivnost i poboljšao subjektivne rezultate aktivnosti, ponašanja, kvalitete života, temperamenta i sreće mačaka.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE NATURE/TYPE: Cardboard box 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU OSOBINE/TIP: Kartonska kutija
Administer subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/kg). 
Primijenite supkutano na mačkama ili psima oko 30 minuta prije početka kirurškog zahvata, primjerice oko vremena indukcije opće anestezije, u dozi od 1 ml po 10 kg tjelesne težine (2 mg/kg).
Differences between robenacoxib and placebo were significant (P<0.05) for the client specific outcome measures, but did not reach significance (P=0.07) for the feline musculoskeletal pain index. 
Razlike između rebenakoksiba i placeba bile su značajen (P < 0,05) kod rezultata mjerenja specifičnih za klijenta, ali nisu postigle znatnu razinu (P = 0,07) za indeks mišično-koštanog bola kod mačaka.
Robenacoxib 20 mg 
Robenakoksib 20 mg
Therapy should be discontinued if liver enzyme activities increase markedly or the dog shows clinical signs such as anorexia, apathy or vomiting in combination with elevated liver enzymes. 
Liječenje treba prekinuti ako su aktivnosti jetrenih enzima u znatnom porastu ili ako pas pokazuje kliničke znakove poput anoreksije, apatije ili povraćanja u kombinaciji s povišenim razinama jetrenih enzima.
20 to < 40 
20 do <40
Vomiting and soft faeces were very common, decreased appetite and diarrhoea were common, and blood in the faeces was uncommon. 
Povraćanje i mekana stolica vrlo su često zabilježeni, smanjeni apetit i proljev bili su česti, a krv u fecesu bila je manje česta.
Keep the vial in the outer carton. 
Čuvati bočicu u vanjskom pakovanju.
In artificially induced inflammation in cats and dogs, robenacoxib reduced pain, inflammation and fever at the recommended doses with a rapid onset of action (1 h). 
U umjetno izazvanoj upali u mačaka i pasa robenakoksib je ublažio bol, upalu i vrućicu u preporučenim dozama, uz brz početak djelovanja (1 h).
In vivo, robenacoxib solution for injection produced marked inhibition of COX-2 activity and had no effect on COX-1 activity. 
In vivo, otopina robenakoksiba za injekciju uzrokovala je znatnu inhibiciju aktivnosti COX-2 i nije utjecala na aktivnost COX-1.